Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is one of the most common hematological malignancies with high heterogeneity, characterized by a differentiating block at the early progenitor stage. The selective BCL-2 inhibitor, Venetoclax (Ven), has shown exciting clinical results in a certain group of AML patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chan, Gu, Yan, Ge, Zheng, Song, Chunhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569949/
https://www.ncbi.nlm.nih.gov/pubmed/36232694
http://dx.doi.org/10.3390/ijms231911393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569949/
https://www.ncbi.nlm.nih.gov/pubmed/36232694
http://dx.doi.org/10.3390/ijms231911393

Ejemplares similares